All raw data par li lei (22680179)

Sujets:

Original data for figure in the article<b> “</b><b>Genome-wide characterization of Toll-like receptor genes in </b><b><i>Oreochromis niloticus</i></b><b> and their involvement in b... par Xitan Hou (22677809)

Sujets: “…Nile tilapia, Toll-like receptor, Streptococcus agalactiae; Brain immune response…”

Context-dependent serotonin signaling links dietary quality to foraging decisions par Likui Feng (20765370)

Sujets: “…C. elegans, dietary quality, serotonin, serotonin receptor, neural circuits…”

Supplementary file 1_Adopting orphan receptors: zebrafish Tlr4 homologs mediate responses to group IX/X transition metals.docx par Aaron P.D. Fox (22686512)

Sujets:

Table 1_Single-cell transcriptome analysis reveals elongation and ossification characteristics of antlers.doc par Ruobing Han (8460432)

Sujets:

Table 3_Single-cell transcriptome analysis reveals elongation and ossification characteristics of antlers.xlsx par Ruobing Han (8460432)

Sujets:

Table 2_Single-cell transcriptome analysis reveals elongation and ossification characteristics of antlers.xlsx par Ruobing Han (8460432)

Sujets:

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic N... par Xinhang Gu (22686224)

Sujets: “…epidermal growth factor receptor…”

Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy par Amr El Zawily (14851115)

Sujets:

Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy par Amr El Zawily (14851115)

Sujets:

Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy par Amr El Zawily (14851115)

Sujets:

Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy par Amr El Zawily (14851115)

Sujets:

Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy par Amr El Zawily (14851115)

Sujets:

Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy par Amr El Zawily (14851115)

Sujets:

Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy par Amr El Zawily (14851115)

Sujets:

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models par Katie E. Hebron (15046889)

Sujets:

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models par Katie E. Hebron (15046889)

Sujets:

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models par Katie E. Hebron (15046889)

Sujets:

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma par Yuncheng Bei (16546095)

Sujets:

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma par Yuncheng Bei (16546095)

Sujets: